Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) Shares Outstanding (Weighted Average) (2016 - 2025)

Marimed (MRMD) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $390.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 2.9% to $390.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $390.1 million through Dec 2025, up 2.9% year-over-year, with the annual reading at $390.1 million for FY2025, 2.9% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $390.1 million at Marimed, down from $392.6 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $392.6 million in Q3 2025, with the low at $305.2 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $355.3 million, with a median of $355.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) surged 32.22% in 2021, then rose 1.77% in 2025.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $326.5 million in 2021, then increased by 3.44% to $337.7 million in 2022, then rose by 7.61% to $363.4 million in 2023, then grew by 4.33% to $379.2 million in 2024, then rose by 2.9% to $390.1 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $390.1 million, $392.6 million, and $386.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.